Autor(es): Matos, Liliana ; Gonçalves, Mariana ; Santos, Juliana Inês ; Coutinho, Maria Francisca ; Prata, Maria João ; Omidi, Maryam ; Pohl, Sandra ; Alves, Sandra
Data: 2023
Identificador Persistente: http://hdl.handle.net/10400.18/9150
Origem: Repositório Científico do Instituto Nacional de Saúde
Assunto(s): Mucolipidosis II; Lysosomal Storage Disorder; Genética Humana; Doenças Genéticas
Introduction: Mucolipidosis II (ML II) is a Lysosomal Storage Disorder caused by the deficiency of the enzyme GlcNAc-1-phosphotransferase, which is responsible for the Mannose-6-Phosphate marker addition to lysosomal enzymes. Of all ML II mutations, the c.3503_3504delTC in GNPTAB exon 19 is the most frequent, making it a good target for a personalized therapy. Here, we explored an innovative therapeutic strategy based on the use of antisense oligonucleotides (ASOs) for ML II. Previously, on ML II patients’ fibroblasts, ASOs were used to skip exon 19 of the GNPTAB pre-mRNA, successfully resulting in the production of an in-frame mRNA. Now, our aim is to analyze if these results are translated to the enzymatic and cellular phenotype level.
